Shares of Akorn (NASDAQ: AKRX) jumped over 14% on Monday after the company announced multiple regulatory approvals. The specialty generic-pharmaceutical leader said Abbreviated New Drug Applications (ANDAs) have been accepted by the U.S. Food and Drug Administration for its fluticasone propionate nasal spray and loteprednol etabonate ophthalmic suspension.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,